Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.

Author: BaiJianling, ChenJun, ChenPengsheng, EikelboomJohn W, GongXiaoxuan, KongDeyu, LiChunjian, LiuJie, MengHaoyu, XuLei, YangZhijian, ZouFengwei

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This meta-analysis of 19 trials involving 7,464 patients compared cilostazol-based triple antiplatelet therapy (TAPT) with dual antiplatelet therapy (DAPT) in patients undergoing coronary stent implantation. TAPT improved angiographic outcomes and reduced the risk of target lesion revascularization (TLR) and target vessel revascularization (TVR), but did not reduce major cardiovascular events and was associated with an increase in minor adverse events.
Paper Details　
Original Abstract of the Article :
The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We sea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11239-014-1090-5

データ提供：米国国立医学図書館（NLM）

Balancing Benefits and Risks: Cilostazol in Triple Antiplatelet Therapy

The delicate balance between preventing cardiovascular events and managing bleeding risks is like navigating a treacherous desert, carefully choosing each step to ensure survival. This study explores the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT) compared to dual antiplatelet therapy (DAPT) in patients undergoing coronary stent implantation. The researchers meticulously analyzed data from numerous randomized controlled trials, providing a comprehensive overview of the benefits and risks associated with these treatments.

Cilostazol-Based TAPT: A Mixed Bag of Outcomes

The meta-analysis reveals that TAPT offers some benefits, including improved angiographic outcomes and a lower risk of target lesion revascularization (TLR) and target vessel revascularization (TVR). This is like finding a hidden oasis in the desert, providing a source of relief and improvement in certain areas. However, TAPT does not significantly reduce the risk of major cardiovascular events and is associated with an increased risk of minor adverse events, like encountering a brief sandstorm along the journey.

Navigating the Complexities of Antiplatelet Therapy

This study underscores the complexities of antiplatelet therapy, highlighting the need for careful consideration of the potential benefits and risks. It's like navigating a complex desert ecosystem, where each intervention can have both positive and negative consequences. The findings emphasize the importance of individualized treatment decisions, tailored to the specific needs and risks of each patient.

Dr.Camel's Conclusion

This meta-analysis provides valuable insights into the use of cilostazol-based TAPT in patients undergoing coronary stent implantation. It's like discovering a new path in the desert, offering both promising opportunities and potential pitfalls. The findings encourage a careful and nuanced approach to antiplatelet therapy, considering the individual needs and risks of each patient to ensure a safe and effective journey.

Date :
  1. Date Completed 2015-09-16
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24869717

DOI: Digital Object Identifier

10.1007/s11239-014-1090-5

Related Literature

Article Analysis
・Side Effects of cilostazol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.